Then you wont read this regarding today's news
"CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that the company has shipped 660 additional vials of its Trappsol® Cyclo™ product to the government of Brazil under a business relationship now in its seventh year."
The highlighted portion is the sizzle --- but where's the steak?
This is an order stemming from a 7 year relationship.
Investors want to know what makes the order special, specifically with respect to volume of units sold and price (i.e. gross proceeds from sale).
IOW - was the 660 units merely a fulfillment of their annual order or was a special order that showed an INCREASE in annuals sales units (which would lead to an increase in annuals sales figures)
If it was significant I would think they would not have mentioned the number of units but rather have announced that they just shipped an order valued at $XXX dollars.
However when put into context the fact that they are in their seventh year of supplying product to the the govt of Brazil ....
... and that "CTD has supplied more than 7200 vials of liquid Trappsol® Cyclo™ ... one can assume it just one of many orders and perhaps / likely smaller than some previous ones since 7200/7 = 1028 units sold per year.
Also; : "CTD has an exclusive supplier agreement with the government of Brazil and distributes to the country through its exclusive distribution partner UnoHealthcare of Miami, FL."
From their website : In 2014, one customer (UNO Healthcare, Inc.) accounted for more than 57% of our total revenue.
One is likely to conclude its just business as usual.
One might also conclude ITS AN UNUSUAL (AND RISKY) BUSINESS THAT SELLS OVER 50% OF ITS PRODUCT TO ONE CUSTOMER IN A GIVEN YEAR.
I'm looking for a reason to bid for some shares but just don't see one yet.
